Drug Type RNA editing |
Synonyms- |
Target |
Action modulators |
Mechanism HTT gene modulators, SHANK3 modulators(SH3 and multiple ankyrin repeat domains 3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autistic Disorder | Preclinical | United States | 15 May 2025 | |
Huntington Disease | Preclinical | United States | 15 May 2025 |